SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (41374)5/20/2014 9:03:22 AM
From: Pogeu Mahone  Read Replies (1) | Respond to of 52153
 
To: Metacomet who wrote (11387)5/20/2014 8:59:55 AM
From: Pogeu Mahone of 11391
Do you have any autoimmune disease?

D3 is very effective for all autoimmune disease if one takes a pharmacutical dose.

It blows my mind people are afraid of D3 in our drug addicted culture.

No side effects. Every totally uninformed doctor tells me I will hurt myself.
They all are fools.

Get a PTH test.
I get another PTH test first week of June.
Last year my PTH=28

All of the experts arond SI and My doctors told me my PTH woiuld be zero or very close to zero.
I only take 50,000 iu daily.

My wife takes 100000 daily and her PTH is 48.

All of these so called experts are 1000% wrong.

lol
Ask your moron doctor, see what he says!

Ask the bioitech valuation thread.
Very smart biotech experts , can make us all a lot of money,
but know dick about D3.
They have bought all of the medical establishmsnts bullshit hook line and sinker.

So they compromise there own health afraid of D3 instead taking some shit pharmacutical with all of the side effects.

lol



To: Biomaven who wrote (41374)10/30/2014 5:02:33 PM
From: ghmm  Read Replies (1) | Respond to of 52153
 
Fibrogen's presentation is on Retail Roadshow

retailroadshow.com

I saw someone tweet the price range of 16-19 which would put the market cap in the 1B range. I have to look at the S-1 to gage my level of interest. I am already interested just on their 2nd most valuable program (IPF). The one thing (from an investor standpoint) is they have advanced it at a painfully slow pace last I knew they were doing additional Phase 2 work.